Palliative surgery in peritoneal carcinomatosis can make a difference of months in the survival of the patient with improved quality of life Published on 29/04/2021 PIPAC, a palliative technique for intraperitoneal administration of chemotherapy, can increase the average survival rate by between 16 and 42 months in patients with peritoneal carcinomatosis
Vaporized chemotherapy administered intraperitoneally offers hopeful results in patients with metastases in the area Published on 11/02/2019 The administration of pressurized intraperitoneal aerosol chemotherapy (PIPAC) offers new treatment options for patients with peritoneal carcinomatosis, that is, with metastases in the peritoneum, who are not candidates for curative surgical treatment. "Intravenous systemic chemotherapy is the standard treatment in patients with advanced cancer which cannot be completely removed due to the great volume of the disease," says Dr. Gloria Ortega, of the Surgical Oncology Service of MD Anderson Madrid. "The problem is that patients in treatment with systemic chemotherapy begin to have numerous complications derived from the treatment," specialist goes on, who points out that PIPAC is treatment that, while used in combination with systemic chemotherapy, "allows the disease to be controlled with fewer adverse effects".